Pexidartinib

Pexidartinib, sold under the brand name Turalio, is a kinase inhibitor drug for the treatment of adults with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery.[2][3][4][5]

Pexidartinib
Clinical data
Trade namesTuralio
Other namesPLX-3397
AHFS/Drugs.comMonograph
MedlinePlusa619050
License data
Pregnancy
category
  • US: N (Not classified yet) [1]
    Routes of
    administration    		By mouth
    ATC code
    • L01EX15 as of 2021
    Legal status
    Legal status
    Identifiers
    CAS Number
    PubChem CID
    IUPHAR/BPS
    DrugBank
    ChemSpider
    UNII
    KEGG
    ChEBI
    ChEMBL
    Chemical and physical data
    FormulaC20H15ClF3N5
    Molar mass417.82 g·mol−1
    3D model (JSmol)

    On 2 August 2019, it was approved by U.S. FDA for treatment of giant-cell tumor of the tendon sheath (GC-TS).[2][6][7]

    Common side effects are increased lactate dehydrogenase (proteins that helps produce energy in the body), increased aspartate aminotransferase (enzymes that are mostly in the liver but also in muscles), loss of hair color, increased alanine aminotransferase (enzymes that are primarily in the liver and kidney) and increased cholesterol.[2] Additional side effects include neutropenia (low level of white blood cells that help the immune system defend against disease and infection), increased alkaline phosphatase (enzymes that are mostly in the cells of bone and the liver), decreased lymphocytes (white blood cells that help the immune system defend against disease and infection), eye edema (swelling around the eyes), decreased hemoglobin (protein in red blood cells that carry oxygen), rash, dysgeusia (altered sense of taste) and decreased phosphate (electrolytes that help with energy).[2]

    The US prescribing information for pexidartinib includes a boxed warning about the risk of serious and potentially fatal liver injury.[2][3]

    Pexidartinib is available in the US only through the Turalio Risk Evaluation and Mitigation Strategy (REMS) Program.[2]

    History

    The approval of pexidartinib was based on the results of a multi-center international clinical trial of 120 subjects, 59 of whom received placebo.[2] The primary efficacy endpoint was the overall response rate (ORR) analyzed after 25 weeks of treatment.[2] The clinical trial demonstrated a statistically significant improvement in ORR in subjects who received pexidartinib, with an ORR of 38%, compared to no responses in subjects who received placebo.[2] The complete response rate was 15% and the partial response rate was 23%.[2] A total of 22 out of 23 responders who had been followed for a minimum of six months following the initial response maintained their response for six or more months, and a total of 13 out of 13 responders who had been followed for a minimum of 12 months following the initial response maintained their response for 12 or more months.[2]

    The U.S. Food and Drug Administration (FDA) granted the application for pexidartinib breakthrough therapy designation, orphan drug designation, and priority review designation.[2] The FDA granted the approval of Turalio to Daiichi Sankyo.[2]

    gollark: Maybe it could be done with some detachable component to do the launch in the air if I was better at docking.
    gollark: On Minmus I just gave it some long landing legs.
    gollark: It would probably recoil itself against the ground.
    gollark: Given the low gravity it would be safe, if annoying, to just raise it a bit during the launch. Except possibly the mass driver recoil would cause problems.
    gollark: I suppose, just adding more reaction wheels and RCS to it would have worked.

    References
    1. "Pexidartinib (Turalio) Use During Pregnancy". Drugs.com. 28 October 2019. Retrieved 19 March 2020.
    2. "FDA approves first therapy for rare joint tumor". FDA (Press release). 2 August 2019. Retrieved 17 August 2019. This article incorporates text from this source, which is in the public domain.
    3. "Turalio- pexidartinib capsule". DailyMed. 7 August 2019. Retrieved 19 March 2020.
    4. "Pexidartinib Hydrochloride Monograph for Professionals". Drugs.com. 19 August 2019. Retrieved 19 March 2020.
    5. "Microglial Magic: Drug Wipes Them Out, New Set Appears". Alzforum. 18 April 2014. Retrieved 19 March 2020.
    6. "Drug Trials Snapshots: Turalio". U.S. Food and Drug Administration (FDA). 2 August 2019. Retrieved 17 March 2020.
    7. "Drug Approval Package: Turalio". U.S. Food and Drug Administration (FDA). 22 July 2019. Retrieved 17 March 2020.

    Further reading
    • "Pexidartinib". Drug Information Portal. U.S. National Library of Medicine.
    • New ATC . WHO Collaborating Centre for Drug Statistics Methodology
    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.